Business Context and Reporting Period
Company: AngioDynamics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 14, 2026
Event: Regulation FD Disclosure regarding a presentation by James Clemmer, President and CEO, at the J.P. Morgan 44th Annual Healthcare Conference.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to disclose the occurrence of a conference presentation and includes the presentation slides as an exhibit, which are not deemed "filed" for liability purposes.
Material Changes
No material changes to financial results or operations are reported in the text of this filing. The document references the company's Annual Report on Form 10-K for the year ended May 31, 2025, for historical risk factors and financial data.
Guidance, Outlook, and Risks
Forward-Looking Statements: The filing contains a standard disclaimer that the presentation slides include forward-looking statements regarding future financial position, results of operations, and business strategy. These are not guarantees and are subject to risks and uncertainties.
Identified Risks: The text lists numerous factors that could cause actual results to differ materially from expectations, including:
- Scale and scope of the COVID-19 global pandemic.
- Product development capabilities and technological advances by competitors.
- Intellectual property infringement or assertions thereof.
- Regulatory actions by the FDA or other agencies.
- Healthcare reforms and government regulations.
- Results of pending or future clinical trials.
- Economic conditions, including inflation, tariffs, labor shortages, and supply chain challenges.
- On-going litigation and product liability claims.
- Foreign currency exchange rate fluctuations.
- Integration of acquired businesses.
Investor Verification Checklist
- Review the attached presentation slides (Exhibit 99.1) for specific strategic updates or qualitative guidance, as the 8-K text itself contains no data.
- Verify the company's most recent audited financial results in the Form 10-K for the year ended May 31, 2025.
- Monitor regulatory filings for updates on pending clinical trials and litigation mentioned in the risk factors.
- Assess the impact of current economic conditions (inflation, tariffs, supply chain) on the company's cost structure as highlighted in the forward-looking statement disclaimer.